Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | NA | High |
Rating | 2.0 | 4.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 2.19 | 1.72 |
NAV | ₹29.98 | ₹74.86 |
Fund Started | 24 May 2010 | 16 Feb 2004 |
Fund Size | ₹274.92 Cr | ₹3165.91 Cr |
Exit Load | Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 months. | Exit load for units in excess of 30% of the investment,1% will be charged for redemption within 1 year |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 9.53% | 10.03% |
3 Year | 8.27% | 10.84% |
5 Year | 9.35% | 11.20% |
1 Year
3 Year
5 Year
Equity | 21.46% | 22.00% |
Cash | 1.55% | 5.06% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
HDFC Bank Ltd. | 2.17% |
ICICI Bank Ltd. | 1.85% |
Reliance Industries Ltd. | 1.65% |
Bajaj Finance Ltd. | 1.45% |
Infosys Ltd. | 1.37% |
Mahindra & Mahindra Ltd. | 1.10% |
Bank Of Baroda | 0.91% |
Bharti Airtel Ltd. | 0.77% |
NTPC Ltd. | 0.67% |
Kotak Mahindra Bank Ltd. | 0.67% |
Name | Assets |
---|---|
ICICI Bank Ltd. | 2.07% |
SBI Life Insurance Company Ltd. | 1.33% |
Sun Pharmaceutical Industries Ltd. | 1.18% |
Maruti Suzuki India Ltd. | 1.13% |
HDFC Bank Ltd. | 1.03% |
Axis Bank Ltd. | 0.94% |
NTPC Ltd. | 0.92% |
HDFC Life Insurance Co Ltd. | 0.79% |
Aurobindo Pharma Ltd. | 0.70% |
Gland Pharma Ltd. | 0.69% |
Name | Devang Shah | Ritesh Lunawat |
Start Date | 05 Apr 2024 | 28 Dec 2020 |
Name
Start Date
Description | The fund seeks to generate regular income through investments in debt and money market securities. | The scheme seeks to generate long-term capital appreciation by investments in money market and debt instruments. |
Launch Date | 24 May 2010 | 16 Feb 2004 |
Description
Launch Date